Trial
NCT05232864
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Lupus Nephritis
Intervention
Secukinumab
Why stopped
Study terminated by sponsor based on a futility analysis of the core study CAIN457Q12301
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-16